Biotechnology · Boston, Massachusetts, United States
$4.81
-0.41% (-$0.02)2026-07-08
Smart-Money SignalNeutral · 50/100— Insiders are net buyers over 90 days ($25K, 4 buys vs 1 sale)
Net Income-$45.4M
EPS$-0.57
Market Cap$384.9M
Price Performance
Historical data including institutional events
Company Profile
J
Jean-Pierre Sommadossi
CEO & Executive Director
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
- Founded
- 2012
- Employees
- 55
- Headquarters
- Boston, Massachusetts, United States
- Website
- ateapharma.com
Peer ComparisonRevenue ($B)
▾Loading company sections...